Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine and dihydroartemisinin-piperaquine for uncomplicated falciparum malaria in Sudan
ACTRN12618001800213Phase 4Completed
- Sponsor
- Ministry of Health
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of artemether + lumefantrine and dihydroartemisinin + piperaquine in malaria and Falciparum malaria (PF) (2 arms), sponsored by Ministry of Health. Primary endpoints: PCR-corrected treatment failure rate, Adequate clinical and parasitological response and 1 more. Started Oct 2019; status: completed.
02
Drugs
artemether + lumefantrinedihydroartemisinin + piperaquine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12618001800213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001800213.